The Sosei Group Corporation (TYO: 4565) has acquired Swiss biotech Idorsia’s (SIX: IDIA) pharma business in Japan and Asia Pacific, excluding China.
In those territories, the group - which goes by the brand name Sosei Heptares - picks up rights to a pipeline of medicines from Idorsia’s portfolio, with lead product Pivlaz (clazosentan) already commercially available and with fast-growing sales in Japan following a successful launch last year.
"A step change in delivering on our ambitious growth strategy"Another drug seen as having significant growth potential is daridorexant. A Japanese filing is expected next year for insomnia for a product that is marketed in the USA and Europe as Quviviq.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze